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RESEARCH
Randomized sham controlled 
trial of cranial microcurrent stimulation 
for symptoms of depression, anxiety, pain, 
fatigue and sleep disturbances in women 
receiving chemotherapy for early-stage breast 
cancer
Debra Lyon1*, Debra Kelly1, Jeanne Walter2, Harry Bear3, Leroy Thacker2 and Ronald K Elswick2
Abstract 
Purpose: Women with breast cancer may experience symptoms of depression, anxiety, pain, fatigue and sleep 
disturbances during chemotherapy. However, there are few modalities that address multiple, commonly occurring 
symptoms that may occur in individuals receiving cancer treatment. Cranial electrical stimulation (CES) is a treatment 
that is FDA cleared for depression, anxiety and insomnia. CES is applied via electrodes placed on the ear that deliver 
pulsed, low amplitude electrical current to the head.
Methods: This phase III randomized, sham-controlled study aimed to examine the effects of cranial microcurrent 
stimulation on symptoms of depression, anxiety, pain, fatigue, and sleep disturbances in women receiving chemo-
therapy for early-stage breast cancer. Patients were randomly assigned to either an actual or sham device and used 
the device daily for 1 h. The study was registered at clinicaltrials.gov, NCT00902330.
Results: The sample included N = 167 women with early-stage breast cancer. Symptom severity of depression, 
anxiety, and fatigue and sleep disturbances were generally mild to moderate. Levels of pain were low. Anxiety was 
highest prior to the initial chemotherapy and decreased over time. The primary outcome assessment (symptoms of 
depression, anxiety, fatigue, pain, sleep disturbances) revealed no statistically significant differences between the two 
groups, actual CES vs. sham.
Conclusion: In this study, women receiving chemotherapy for breast cancer experienced multiple symptoms in the 
mild to moderate range. Although there is no evidence for the routine use of CES during the chemotherapy period for 
symptom management in women with breast cancer, further symptom management modalities should be evaluated 
to mitigate symptoms of depression, anxiety, fatigue, pain and sleep disturbances over the course of chemotherapy.
© 2015 Lyon et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
The American Cancer Society in 2015 projected that in 
the United States, there will be 231,840 women diag-
nosed with breast cancer (Siegel et  al. 2015). Most 
women will be diagnosed in the early stages of the disease 
(Stage I and II) and 90% of these individuals can expect to 
survive at least 5 years due to improvements in adjuvant 
chemotherapy and targeted hormonal therapies (Siegel 
et  al. 2012). However, cancer treatments, and, perhaps 
the cancer itself, contribute to a number of distressing 
symptoms. In particular, the administration of systemic 
chemotherapy is associated with multiple, co-occurring 
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distressing symptoms (Dodd et  al. 2010; Goedendorp 
et al. 2008), which include depressive symptoms (Badger 
et al. 2007), anxiety (Badger et al. 2007), fatigue (Berger 
et  al. 1997), and pain (Utne et  al. 2010; Valeberg et  al. 
2008). In women with breast cancer, anxiety and sleep 
disturbances (Lee et  al. 2004) are also common dur-
ing the adjuvant chemotherapy treatment phase. These 
symptoms, both individually and collectively, are strongly 
associated with decreased quality of life. In addition to 
the distress related to these common symptoms, fatigue, 
depression, and physical complaints are associated with 
poor employment outcomes for breast cancer (Hansen 
et al. 2008).
Because symptoms tend to occur together and may 
have synergistic negative effects on quality of life, there 
is a movement towards examining “clusters” of co-
occurring symptoms in persons with cancer and for 
testing interventions that might be effective for amelio-
rating more than one symptom (Dodd et al. 2001). Pain, 
depression, and fatigue have been identified as compo-
nents of a notable cluster that may also include anxiety 
and sleep disturbances. Collectively, these symptoms 
can be described as “psychoneurological symptoms” 
(PNS) (Lyon et  al. 2013). PNS may result in a signifi-
cant decline in quality of life by contributing to adverse 
health outcomes over the active treatment period and 
into survivorship. To date, conventional therapies have 
not been effective for treating multiple concurrent symp-
toms. Given the limitations of conventional modalities 
for symptom management, many breast cancer patients 
report using a complementary or alternative medicine 
(CAM) modality in conjunction with conventional can-
cer treatment (Saghatchian et al. 2014). CAM is defined 
as “a group of diverse medical and health care systems, 
practices, and products that are not presently considered 
to be part of conventional medicine” (National Cancer 
Institute website). The most common reason given for 
using CAM modalities in individuals with cancer is the 
belief that CAM will assist with relieving pain and con-
trolling side effects related to disease or treatment (Man-
sky and Wallerstedt 2006).
Cranial electrical microcurrent stimulation (CES) is 
a non-invasive modality that falls under the category 
described by the National Center for Complemen-
tary and Alternative Medicine (NCCAM) as “Veritable 
Energy Medicine.” The putative mechanism of CES is not 
completely understood; however, there are several inter-
related theories of the mechanism of action of applied 
“energy” modalities. Both high and low intensity energy 
modalities are thought to initiate neuromodulation. 
High intensity energy modalities such as repetitive tran-
scranial magnetic stimulation (rTMS) have now entered 
main stream psychiatric and neurologic practice. The 
mechanism for rTMS is thought to include the activation 
or inhibition of cortical activity depending on stimula-
tion parameters. In contrast, the mechanism of action for 
low-intensity AC stimulation is less clear. CES is a form 
of alternating current (AC) stimulation that involves the 
application of current to infra- or supra-auricular struc-
tures (e.g., the ear lobes). Evidence from EEG suggests 
that CES leads to changes in alpha and beta frequency 
ranges, indicating potential neuroplastic and cognitive 
effects. Schroeder and Barr (2001) measured EEG activity 
during sham and AC stimulation and showed increases 
in low alpha (8–12 Hz) and high theta (3–8 Hz) activity 
(Schroeder and Barr 2001). A second hypothesis for the 
effects of CES effects of cranial AC stimulation is that 
CES has a primary effect on the peripheral nervous sys-
tem that is secondarily transmitted to the central nervous 
system (Zaghi et al. 2009). CES may render its effects not 
by polarizing brain tissue, but rather via rhythmic stim-
ulation that synchronizes and enhances the efficacy of 
endogenous neurophysiologic activity (Zaghi et al. 2009). 
Additionally, increases in blood and cerebrospinal fluid 
levels of specific neurotransmitters, including serotonin, 
norepinephrine, dopamine, and β-endorphin have been 
reported when CES was used for both 1 and 2  weeks 
(Shealy et al. 1998).
Although CES has been used as a modality for treat-
ing symptoms of depression, anxiety and insomnia in 
multiple studies over many years, results have not yet 
reached mainstream acceptance, possibly due to the lack 
of rigorously designed randomized clinical trials. There 
are many studies that have found positive effects of CES 
(Klawansky et al. 1995); however, most studies have not 
been methodologically rigorous. Most have been open 
trials, have had relatively small samples, and few have had 
designs that have included sham devices (Mindes et  al. 
2015). Yet, CES has several advantages over most cur-
rent symptom management strategies and other CAM 
modalities that make its consideration worthwhile. As 
a self-administered, relatively low-cost, and portable 
modality, CES can be used in the home without disrupt-
ing daily routines already taxed by the demands of cancer 
treatments. Given the importance of examining innova-
tive symptom management modalities in oncology prac-
tice for multiple, concurrent symptoms, the primary 
aim of this study was to examine the effects of CES on 
symptoms of depression, anxiety, pain, fatigue and sleep 
disturbances in women receiving chemotherapy for 
early-stage breast cancer.
Methods
Study design
The study was conducted in accordance with the Dec-
laration of Helsinki and was approved by the Virginia 
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Commonwealth University Institutional Review Board. 
Women with newly diagnosed stage I–IIIA breast can-
cer, scheduled to receive at least four cycles of adjuvant 
or neoadjuvant chemotherapy were referred by oncolo-
gists in the Massey Cancer Center and its affiliate sites 
from June 2009 through December 2012. Women were 
included in the sample if they had a diagnosis of stages 
I–IIIA breast cancer; a performance score <2 using the 
Eastern Cooperative Oncology Group criteria; and were 
scheduled to receive at least four cycles of adjuvant or 
neoadjuvant chemotherapy. Women were excluded from 
the study if they had: (1) previous chemotherapy; (2) 
dementia; (3) active psychosis; (4) history of seizure dis-
order; (5) any implanted electrical device, or (6) began 
or changed a medication regimen for depression or 
other psychiatric condition within 30 days prior to study 
enrollment.
After informed consent was obtained, participants’ 
medical records were abstracted for medical history 
and current medication use. The timing of the baseline 
data collection varied depending on patients’ start day 
of chemotherapy, but was always within 48 h of the ini-
tial chemotherapy. During the study, each participant 
was required to use the CES device daily for 1  h until 
2  weeks after chemotherapy cessation. Symptom data 
were collected weekly. All participants completed a log to 
record CES use and the number of times that the device 
was used was assessed weekly. The time to complete all 
questionnaires at each time point was approximately 
30 min. All data were collected either at the Massey Can-
cer Center and its affiliate sites (the initial, midpoint and 
post-chemotherapy data were collected in person) or via 
a weekly telephone call with study personnel.
Intervention
The researchers conducted this study using an Alpha-
Stim cranial electrotherapy stimulator. Both the active 
and sham devices were provided on loan by Electro-
medical Products International, (2201 Garrett Mor-
ris Parkway, Mineral Wells, TX 76067-9034). The CES 
unit (Alpha-Stim® 100 Microcurrent Stimulator) passes 
microcurrent levels of biphasic electrical stimulation via 
ear-lobe electrodes. The CES unit was preset to provide 
1 h of 100 μA (sub-sensory level), modified square-wave 
biphasic stimulation on a 50% duty cycle at .5 Hz, and to 
automatically turn off at the end of 1 h. CES devices were 
pre-set at the factory to provide a maximum of 60 min of 
modified square-wave biphasic stimulation at 0.5 Hz and 
100 μA, the lowest setting below the level of perception. 
Sham devices were identical; however, the electrodes did 
not transmit a current. Because the devices were pre-set 
at the factory, participants were unable to change the set-
tings. The devices were dispensed by the investigation 
pharmacy. Participants were instructed to use the device 
for 1 h each daily.
Power analysis
Data from our pilot, feasibility study (Lyon et  al. 2010) 
was used to estimate mean values, correlations, and 
model-fitting mean square errors for power computa-
tions. Power calculations were computed using SASv9.1. 
The sample size for the proposed study was 166 partici-
pants, from which we assumed a 10% attrition rate, simi-
lar to the attrition rate in our preliminary study, yielding 
a final sample size of 150. Power analysis was performed 
for repeated measures assuming an overall a = 0.05 and 
a power of 90%. A Bonferroni correction was made to 
adjust for multiplicity resulting from five dependent 
variables, thus reducing each symptom alpha level to 
0.05/5 = 0.01.
Randomization
Participants were randomized using a computer-gener-
ated random number sequence with a block size of four. 
Randomization was stratified based on two treatment 
regimen groups: those who received chemotherapy every 
2  weeks and those who received chemotherapy every 
3  weeks. Treatment assignments were blinded to the 
study investigators and patients.
Measures
In addition to a demographic questionnaire that included 
details about the stage and characteristics of the breast 
cancer diagnoses, comorbidities and life-style habits, 
several validated symptom measures were used to col-
lect symptom data. The Hospital Anxiety and Depres-
sion Scale (HADS) is a 14-item self-report questionnaire 
developed to detect the presence and severity of both 
anxiety and depressive symptoms at the time of report-
ing. Participants rate (0–3) the severity of each symptom 
over a 7-day period. The possible score on the subscales is 
0–21 for depression or anxiety and a possible total scale 
score of 0–42. The HADS has well-established reliability 
and validity for both depression and anxiety in women 
with breast cancer (Zigmond and Snaith 1983).
The brief pain inventory (BPI) short-form is a pain 
assessment tool that has well-established reliability and 
validity for adult patients with no cognitive impairment 
in trajectory studies of cancer and its symptoms. The 
BPI assesses the severity of pain, location of pain, pain 
medications, amount of pain relief in the past 24 h or the 
past week, and the impact of pain on daily functions. The 
“Usual pain” item was used to measure pain severity over 
time in this study (Cleeland and Ryan 1994).
The brief fatigue inventory (BFI) is a 9-item scale that 
taps into a single dimension of fatigue severity and the 
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interference fatigue creates in daily life. The BFI is a clini-
cally validated tool used to assess cancer-related fatigue 
and its impact on daily functioning. The “Usual fatigue” 
item was used to measure severity of fatigue over time 
(Mendoza et al. 1999).
The General Sleep Disturbance Scale (GSDS) is a 
21-item scale that consists of 21 items that evaluate vari-
ous aspects of sleep disturbance (quality and quantity of 
sleep, sleep onset latency, number of awakenings, exces-
sive daytime sleepiness, and medication use) over the 
past week (Lee 1992). Items are rated on a scale ranging 
from 0 (never) to 7 (every day). The 21 items are summed 
to produce a total score with a possible range from 0 (no 
sleep disturbance) to 147 (extreme sleep disturbance).
Adverse events (AEs) were assessed over the phone at 
week weekly and in person at the mid-point chemother-
apy data collection and at the final data collection two 
weeks after completion of chemotherapy by asking the 
participants the open-ended question: How are you feel-
ing? AEs were reported by the investigator regardless of 
whether they were deemed to be related to the treatment. 
AEs were graded using the most current version of the 
National Cancer Institute Current Toxicity Criteria.
Statistical analysis
Descriptive statistics were used to describe participants’ 
clinical and demographic characteristics, and the level of 
symptoms at each of the study time points. A longitudi-
nal repeated measures model was used to compare the 
effects of the CES intervention group to the sham group 
over the chemotherapy treatment period until final data 
collection two weeks after the final chemotherapy. Data 
of all participants was entered into a secure study data-
base. All participants with any post-baseline data were 
included in the final analyses on a per protocol basis. The 
primary endpoints of levels of depressive symptoms, anx-
iety, pain, fatigue and sleep disturbances were analyzed 
using a longitudinal repeated measures model which 
included one between subjects variable (Group: CES or 
Sham), one within subject factor (visit period: baseline 
period, treatment period, post-treatment period) and the 
interaction between group and visit. Participants with In 
addition to these factors, the model included covariates 
for age (years), menopausal status (pre- or post-meno-
pausal) and body mass index (kg/m2). We tested a variety 
of variance–covariance structures including compound-
symmetry, AR(1) and unstructured; the structure that fit 
the data and provided the most parsimonious model was 
used. The outcome variables for the baseline period were 
constructed from either 1 or 2 observations (number of 
observations M  =  1.02, SD  =  0.14) averaged for each 
subject, while the outcome variables for the treatment 
period were constructed from the mean of 2–11 (number 
of observations M =  5.91, SD =  1.62) observations per 
subject and the outcome variables for the post-treatment 
period were constructed from the mean of 1–22 (number 
of observations M =  9.99, SD =  4.53) observations per 
subject.
Results
A total of 167 women were consented and enrolled to 
participate in this study. A flow diagram (Additional 
file 1: Fig. S1) details the progress of the prospective and 
actual participants through the trial.
Sample characteristics
The mean age of participants was 51 ± 0.78 years. Table 1 
describes demographic characteristics of participants 
and the differences between groups. Other clinical char-
acteristics such as hormone status and treatments (type, 
timing, and duration of chemotherapy) are reported in 
Table 2. The majority of women (88.3%) had infiltrating 
ductal carcinoma and were diagnosed as having stage 
II (61.4%) breast cancer in accordance with criteria set 
by the American Joint Committee on Cancer and most 
participants (53.4%) had grade 3 tumors. The major-
ity of participants were white (61.7%), married (57.7%), 
had greater than a high school education (82.0%), and 
were currently non-smokers (80.1%). Group equiva-
lence differences in the active group and sham group for 
demographic characteristics and clinical factors were 
examined by conducting t-tests and Chi square analyses 
and there were no significant differences between groups.
Levels of psychoneurologic symptoms over time
Women in both groups reported having multiple concur-
rent symptoms across all time points, however, the level 
of symptoms were relatively low. Anxiety levels were 
highest at baseline and decreased over time while depres-
sive and fatigue symptoms increased over time. Levels 
of pain and sleep disturbances fluctuated slightly across 
time; however they remained relatively stable through-
out treatment and after chemotherapy cessation. Fatigue 
scores were lowest at baseline and trended upward over-
time with highest scores at time point three after chemo-
therapy treatment had ended. Table  3 demonstrates the 
values of PNS over time for each group and differences 
between the CES and sham groups.
Group differences in primary outcome measures
There were no statistically significant group differences 
in levels of depression, anxiety, pain, fatigue and sleep 
disturbance (Table  4) at any of the study measurement 
points (pre-chemotherapy, mid-chemotherapy, and/or 
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two weeks after completion of chemotherapy). There was 
also no time by group interaction.
Adverse events
One participant in the actual CES group had a seizure on 
a day when she did not use the device. The AE was con-
sidered to be unrelated to her usage of the CES device. 
She was removed from the study after the AE occurred.
Discussion
This double-blind, sham-controlled clinical trial did not 
detect any difference between the CES and sham CES 
for reducing psychoneurologic symptoms in women 
with early-stage breast cancer receiving chemotherapy. 
The low level of symptoms contrasts with prior studies 
such as a cohort study of 222 women with early breast 
cancer which found a point prevalence of depression, 
anxiety, or both (including borderline cases) was 33% at 
diagnosis (Burgess et  al. 2005). In a study of 94 women 
with early-stage breast cancer that used Paroxetine for 
decreasing levels of depression and fatigue, 26 (28%) 
patients were significantly depressed at baseline, using 
a CES-D score of 19 or greater to indicate depression 
(Roscoe et al. 2005). Given that levels of symptoms were 
generally lower than anticipated it is possible that a floor 
effect mitigated potential benefits of CES in this sample. 
This contrasts with a double-blinded sham controlled 
trial of 115 participants with a primary diagnosis of an 
anxiety disorder, found significant positive effects of CES 
vs. sham for reducing symptoms of anxiety (p =  0.001, 
d = 0.94) and depression (p = 0.001, d = 0.78) from base-
line to endpoint of the study (Barclay and Barclay 2014).
In this study of CES in women with breast cancer, 
we found that while most symptoms were in the mild 
range, the symptoms had different trajectories over 
time. Anxiety levels were highest at baseline, while 
depressive symptoms increased over time. These lev-
els of similar to a recent longitudinal study of women 
with early-stage breast cancer that also found that pre-
chemotherapy anxiety scores were significantly (p < 0.05) 
worse at baseline than cycle 4 day 1, whereas depression 
scores were significantly worse during treatment than at 
Table 1 Demographic characteristics
* t-test.
** Chi-square test.
Sham (N = 81) Active (N = 82) Total (N = 163) P-value
Age (mean ± standard error) 51.91 ± 0.97 51.04 ± 1.21 51.47 ± 0.78 0.57*
BMI (mean ± standard error) 30.61 ± 0.87 30.74 ± 0.99 30.68 ± 0.66 0.92*
Leisure Activity Score (mean ± standard error) 25.30 ± 2.99 22.44 ± 2.56 23.86 ± 1.96 0.47*
Life Style Scores (mean ± standard error) 2.82 ± 0.05 2.85 ± 0.04 2.84 ± 0.03 0.66*
Race (count (%))
 White 53 (65.43%) 48 (58.54%) 101 (61.96%) 0.37**
 Other 28 (34.57%) 34 (41.46%) 62 (38.04%)
Education (count (%))
 ≤HS 17 (21.52%) 12 (14.63%) 29 (18.01%) 0.26**
 >HS 62 (78.48%) 70 (85.37%) 132 (81.99%)
Marital status (count (%))
 Currently married 46 (56.79%) 48 (58.54%) 94 (57.67%) 0.82**
 Not currently married 35 (43.21%) 34 (41.46%) 69 (42.33%)
Employment
 FT 44 (55.00%) 39 (47.56%) 83 (51.23%) 0.34**
 Not FT 36 (45.00%) 43 (52.44%) 79 (48.77%)
Menopausal status (count (%))
 Pre 30 (37.04%) 40 (48.78%) 70 (42.94%) 0.13**
 Post 51 (62.96%) 42 (51.22%) 93 (57.06%)
Smoking status (count (%))
 Yes 20 (24.69%) 11 (13.41%) 31 (19.02%) 0.07**
 No 61 (75.31%) 71 (86.59%) 132 (80.98%)
Alcohol use (count (%))
 Yes 41 (50.62%) 43 (52.44%) 84 (51.53%) 0.82**
 No 40 (49.38%) 39 (47.56%) 79 (48.47%)
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Table 2 Clinical characteristics
Sham (N = 81) Active (N = 82) Total (N = 163) P-value
Surgery (count (%))
 Mastectomy 25 (31.25%) 29 (35.80%) 54 (33.54%) 0.28*
 Minimal surgery 29 (36.25%) 20 (24.69%) 49 (30.43%)
 Other 26 (32.50%) 32 (39.51%) 58 (36.02%)
Histology (count (%))
 IDC 76 (93.83%) 68 (82.93%) 144 (88.34%) 0.03**
 Other 5 (6.17%) 14 (17.07%) 19 (11.66%)
Grade (count (%))
 1 5 (6.17%) 6 (7.32%) 11 (6.75%) 0.95*
 2 32 (39.51%) 33 (40.24%) 65 (39.88%)
 3 44 (54.32%) 43 (52.44%) 87 (53.37%)
Stage (count (%))
 I 21 (25.93%) 16 (19.51%) 37 (22.70%) 0.25*
 IIA 31 (38.27%) 27 (32.93%) 58 (35.58%)
 IIB 15 (18.52%) 27 (32.93%) 42 (25.77%)
 IIIA 13 (16.05%) 12 (14.63%) 25 (15.34%)
 IIIB 1 (1.23%) 0 (0.00%) 1 (0.61%)
Chemotherapy (count (%))
 AC 4 (4.94%) 7 (8.75%) 11 (6.83%) 0.49*
 AC followed by Taxane 35 (43.21%) 29 (36.25%) 64 (39.75%)
 CMF 1 (1.23%) 0 (0.00%) 1 (0.62%)
 TC 31 (38.27%) 37 (46.25%) 68 (42.24%)
 Other 10 (12.35%) 7 (8.75%) 17 (10.56%)
Neoadjuvant
 Yes 26 (32.00%) 23 (28.00%) 49 (30.10%) 0.50**
 No 55 (68.00%) 59 (72.00%) 114 (69.90%)
Duration of chemotherapy (weeks) 15.93 ± 5.37 16.47 ± 5.42 16.20 ± 5.39 0.54*
Lymphnodes (count (%))
 Yes 35 (44.30%) 44 (53.66%) 79 (49.07%) 0.24**
 No 44 (55.70%) 38 (46.34%) 82 (50.93%)
Hormonal therapy (count (%))
 Yes 40 (51.95%) 48 (59.26%) 88 (55.70%) 0.36**
 No 37 (48.05%) 33 (40.74%) 70 (44.30%)
Estrogen receptor (count (%))
 Yes 42 (51.85%) 48 (58.54%) 90 (55.21%) 0.39**
 No 39 (48.15%) 34 (41.46%) 73 (44.79%)
HER2 NeuExpression (count (%))
 Yes 15 (18.52%) 24 (29.27%) 39 (23.93%) 0.11**
 No 66 (81.48%) 58 (70.73%) 124 (76.07%)
Progesterone receptor (count (%))
 Yes 34 (41.98%) 33 (40.24%) 67 (41.10%) 0.82**
 No 47 (58.02%) 49 (59.76%) 96 (58.90%)
LongActingOpiods (count (%))
 Yes 16 (19.75%) 19 (23.17%) 35 (21.47%) 0.60**
 No 65 (80.25%) 63 (76.83%) 128 (78.53%)
NonSteroidal analgesics (count (%))
 Yes 20 (24.69%) 10 (12.20%) 30 (18.40%) 0.04**
 No 61 (75.31%) 72 (87.80%) 133 (81.60%)
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pre-chemotherapy (p < 0.05) (Sanford et al. 2010; Ancoli-
Israel et  al. 2014) newly diagnosed breast cancer found 
that depressive symptoms increased after 4  weeks of 
chemotherapy (Rissling et al. 2011). Levels of fatigue and 
pain were low at baseline and fatigue increased over time. 
This finding is consistent with other studies which have 
reported that fatigue increased in prevalence, severity, 
and disruptiveness after the start of treatment (Jacobsen 
et al. 1999). Levels of sleep disturbances were consistent 
over time, comparable to women in third semester of 
pregnancy (Lee and Gay 2004). This finding is similar to 
a recent studies of women with early stage breast cancer 
that found higher levels of sleep disturbances prior to 
chemotherapy, at mid-cycle and 6 months after initiating 
chemotherapy after but little variation in levels over time 
(Sanford et al. 2013).
The utility of CES was not supported in this study. A 
recent meta-analysis concluded that the effects of CES 
over sham did not demonstrate statistical significance 
in reported studies of patients with pain (SMD −0.24, 
95% CI −0.48 to 0.01, P = 0.06). The authors concluded 
that due to this uncertainty, any clinical application of 
this modality would be most appropriate within a clini-
cal research setting rather than in routine clinical care 
(O’Connell 2014). Although CES was not effective in 
this study for reducing symptoms, it is noteworthy 
that few trials have rigorously examined the use of any 
modality for reducing symptoms during the chemo-
therapy treatment period in cancer patients. Under-
treatment of symptoms including depression persists in 
individuals with cancer. A recent study found that one-
fourth of the patients had multiple clinically significant 
symptoms, whereas only 22.5% were free of any clini-
cally significant symptoms (Reece et  al. 2013). Despite 
the widespread use of CAM in persons with cancer, 
there have been few double-blinded randomized trials 
to examine the safety, feasibility and efficacy of CAM 
modalities.
* t-test.
** Chi-square test.
Table 2 continued
Sham (N = 81) Active (N = 82) Total (N = 163) P-value
Anxiolytic (count (%))
 Yes 24 (29.63%) 17 (20.73%) 41 (25.15%) 0.19**
 No 57 (70.37%) 65 (79.27%) 122 (74.85%)
Table 3 Outcome measures by time point (Mean (SD))
Measure Group Time point 1 Time point 2 Time point 3
Anxiety Total 7.34 (4.11) 4.69 (3.46) 4.29 (3.78)
CES 7.09 (4.09) 4.40 (3.19) 4.07 (3.51)
Sham 7.59 (4.13) 4.98 (3.72) 4.51 (4.04)
Depression Total 3.04 (2.62) 4.13 (3.17) 4.55 (3.51)
CES 3.03 (2.48) 4.24 (3.22) 4.47 (3.36)
Sham 3.06 (2.78) 4.02 (3.14) 4.63 (3.67)
Fatigue Total 2.29 (2.81) 3.14 (2.30) 3.33 (2.50)
CES 1.95 (2.71) 3.15 (2.21) 3.34 (2.47)
Sham 2.63 (2.89) 3.14 (2.39) 3.32 (2.55)
Pain Total 1.35 (2.01) 1.17 (1.50) 1.23 (1.72)
CES 1.24 (2.05) 1.25 (1.44) 1.14 (1.65)
Sham 1.45 (1.98) 1.09 (1.56) 1.32 (1.80)
Sleep Total 40.50 (24.28) 40.55 (20.08) 39.70 (20.66)
CES 40.70 (24.83) 38.70 (18.28) 38.50 (20.19)
Sham 40.30 (23.87) 42.44 (21.73) 40.91 (21.21)
Table 4 Analysis of primary outcome variables
Effect Primary outcome variables
Anxiety Depression Fatigue Pain Sleep disturbance
df F p-value df F p-value df F p-value df F p-value df F p-value
Group 1,147 0.77 0.38 1,147 0.04 0.84 1,147 0.02 0.88 1,146 0.00 0.10 1,147 0.13 0.72
Visit 2,144 55.97 <0.01 2,145 17.11 <0.01 2,143 12.77 <0.01 2,143 1.14 0.34 2,143 0.06 0.94
G × V 2,144 0.01 0.99 2,145 0.61 0.55 2,143 1.50 0.23 2,143 2.55 0.08 2,143 0.98 0.38
Age 1,147 12.78 <0.01 1,147 4.26 0.04 1,147 15.34 0.01 1,147 3.46 0.07 1,147 18.36 <0.01
Menopausal status 1,147 2.68 0.10 1,147 2.58 0.11 1,147 16.06 <0.01 1,147 3.78 0.05 1,147 12.48 <0.01
BMI 1,147 0.05 0.82 1,147 0.09 0.76 1,147 0.58 0.46 1,147 3.87 0.05 1,147 0.50 0.48
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Limitations
Several limitations should be considered. In this trial, 
we used a “pragmatic” approach, enrolling women 
with early-stage breast cancer prior to chemother-
apy, regardless of their current or anticipated risk for 
psychoneurologic symptoms (Thorpe et  al. 2009). 
Although this approach led to the recruitment of 
a racially diverse sample of participants and a high 
acceptance rate for the study, it did not, by design, tar-
get participants with a higher risk for symptoms. Due 
to the low severity of symptoms, a possible floor effect 
may have evident, whereby symptoms did not reach the 
threshold for warranting intervention. In the future, 
setting a symptom threshold for inclusion criteria 
should be considered.
Secondly, we had participants with differences in the 
composition of chemotherapy, the number of cycles 
or components of the adjuvant medication such as 
anti-nausea or anxiolytic medications. In addition, 
the use of medications begun after the initiation of 
chemotherapy was not controlled. Thirdly, in a trial 
of this length, because CES was used from the initia-
tion to the completion of chemotherapy, there were 
many different parameters of usage. Some participants 
used CES for as few as 6 weeks and some for as many 
as 32 weeks (depending on their type and schedule of 
chemotherapy). Although there was no statistically 
significant difference in number of weeks by group 
assignment, this wide variability is potentially prob-
lematic. In addition, the dose for CES was set at the 
lowest intensity (sub-sensory) so that the sham could 
be tested. It could be that the dose intensity was not 
adequate for this population. Alternatively, it could be 
that a “nocebo” response was induced by the lack of 
appreciable stimulation delivered by the devices, both 
actual and sham.
Several other potential methodological weaknesses 
are noted. The question used to monitor adverse events 
was general, and not specifically focused on side-effects 
related to CES. However, in the context of cancer treat-
ment, general questions, potentially identifying serious 
adverse events is expected from researchers conduct-
ing clinical trials in patients undergoing active cancer 
treatment. Adherence to CES was also self-reported: 
future trials could consider a more robust technologi-
cal method, such as a counter on the device, to measure 
adherence. In addition, we cannot exclude the possibility 
of a placebo effect in participants in both groups result-
ing from the contact with study personnel. Study person-
nel communicated with the study participants weekly: 
this communication could have been an “intervention” by 
itself.
Conclusion
Further testing of CES in individuals with cancer who 
meet a higher cut-off for levels of symptoms may warrant 
consideration in the future. Although the level of symp-
toms in women in this sample of women with early stage 
breast cancer was relatively mild to moderate, the need 
for tailored symptom management strategies persists for 
cancer patients who are in different stages or treatment 
or who may have elevated psychoneurologic symptoms 
in the survivorship period. However, there is not yet evi-
dence for the utility of CES for routine use in symptom 
management regimens for women with early-stage breast 
cancer during chemotherapy.
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